Coherus Oncology, Inc. (CHRS) Operating margin 2016–2025
Coherus Oncology, Inc. (CHRS) operating margin by fiscal year — reported operating income divided by reported revenue.
-429.5%FY2025 · since FY2016: -61.2% → -429.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -429.5% | +327.1 pp |
| FY2024 | -756.6% | -677.6 pp |
| FY2023 | -79.0% | +42.7 pp |
| FY2022 | -121.7% | -40.9 pp |
| FY2021 | -80.8% | -113.7 pp |
| FY2020 | 32.9% | +2.6 pp |
| FY2019 | 30.3% | — |
| FY2017 | -14918.8% | -14857.6 pp |
| FY2016 | -61.2% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More CHRS financial trends
CHRS RevenueCHRS Net incomeCHRS Net marginCHRS Gross profitCHRS Gross marginCHRS Operating incomeCHRS Operating cash flowCHRS Free cash flowCHRS Capital expendituresCHRS Return on equityCHRS Stock buybacksCHRS Dividends paidCHRS Total assetsCHRS Total liabilitiesCHRS Shareholders’ equityCHRS overview →